Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Stelios Papadopoulos
Age : 72
Public asset : 31,835,043 USD
Country of residence : Unknown
Linked companies : Biogen Inc. - Exelixis, Inc. - Eucrates Biomedical Acquisition Corp. - Regulus Therapeutics Inc.

Biography of Stelios Papadopoulos 
Dr. Stelios Papadopoulos is a Chairman at Eucrates Biomedical Acquisition Corp., a Chairman at Regulus Therapeutics, Inc., a Chairman at Biogen, Inc., a Chairman-Supervisory Board at Biogen GmbH, a Chairman & Treasurer at Fondation Santé, a Chairman at Exelixis, Inc. and an Adjunct Associate Professor at New York University. He is on the Board of Directors at Biogen Idec, Inc. (North Carolina), Diacrin, Inc. (Delaware), National Marrow Donor Program and The BioExec Institute, Inc. Dr. Papadopoulos was previously employed as an Independent Director by BG Medicine, Inc., a Founder by Cellzome Ltd., a Vice Chairman by Cowen & Co. LLC, a Chairman by Anadys Pharmaceuticals, Inc., a President by Instrumentation Laboratory Co., a Chairman by PaineWebber Development Corp., an Investment Banker by PaineWebber, Inc., a Chairman by Cellzome, Inc., and a Vice President-Equity Research Department by Drexel Burnham Lambert, Inc. He also served on the board at GenVec, Inc., SGX Pharmaceuticals, Inc., Biogen Idec New Ventures, Inc., Joule Unlimited Technologies, Inc. and Neuronyx, Inc. He received his graduate degree from New York University, an MBA from New York University and a doctorate degree from New York University.


Current positions of Stelios Papadopoulos 
Holdings of Stelios Papadopoulos 
Stelios Papadopoulos : Personal Network 
Most Read News 
06/22ELON MUSK : Musk says Tesla's new car factories 'losing billions of dollars'
RE
06/28WARREN BUFFETT : Buffett's Berkshire buys more Occidental shares, raises stake to about 16.4%
RE
07/02ELON MUSK : Musk breaks silence on Twitter, posts a picture with the pope
RE
06/29MUKESH AMBANI : Factbox-Ambani children at centre of leadership change at India's Reliance
RE
06/23MARK MILLER : Column-Want to do something about your ailing retirement savings? Don't
RE
06/28RALPH HAMERS : UBS head of strategy to depart bank for entrepreneurship
RE
06/22TREVOR MILTON : Nikola founder Trevor Milton faces new fraud charge
RE
06/22RUPERT MURDOCH : Rupert Murdoch and Jerry Hall are getting a divorce - NYT
RE
06/21ELON MUSK : Musk says there are still a few unresolved matters with Twitter deal
RE
06/23MASAYOSHI SON : Nasdaq listing most likely for Arm - SoftBank's Son
RE
More news


© 2022 People and Ownership :   
Stelios Papadopoulos : Connections 


Latest news about Stelios Papadopoulos 
05/03Biogen's Quarterly Results Fall as Drugmaker Plans to Stop Selling Aduhelm; CEO to Step Down
MT
02/25INSIDER SELL : Exelixis
MT
2021Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.
CI
2021TRANSCRIPT : Exelixis, Inc. Presents at Goldman Sachs 42nd Annual Global Healthcare Conference, Jun-09-2021 01:20 PM
CI
2021TRANSCRIPT : Biogen Inc. - Shareholder/Analyst Call
CI
2021TRANSCRIPT : Exelixis, Inc. - Shareholder/Analyst Call
CI
2020INSIDER TRENDS : Regulus Therapeutics Insider Gets Stock Award, Extends Buy Trend
MT
More news